key: cord-1016165-g7d2fi5o authors: Fan, Bingwen Eugene; Wong, Shiun Woei; Sum, Christina Lai Lin; Lim, Gek Hsiang; Leung, Bernard PuiLam; Tan, Chuen Wen; Ramanathan, Kollengode; Dalan, Rinkoo; Cheung, Christine; Lim, Xin Rong; Sadasiv, Mucheli Shravan; Lye, David Chien; Young, Barnaby Edward; Yap, Eng Soo; Chia, Yew Woon title: Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: Assessing the long‐term outcomes in COVID‐19 patients date: 2022-04-28 journal: Am J Hematol DOI: 10.1002/ajh.26575 sha: c08d62b8f7c227c667c31509f3abe5532d13d826 doc_id: 1016165 cord_uid: g7d2fi5o Sustained hypercoagulability and endotheliopathy are present in convalescent COVID‐19 patients for up to 4 months from recovery. The hemostatic, endothelial, and inflammatory profiles of 39 recovered COVID‐19 patients were evaluated up to 16 months after recovery from COVID‐19. These values were compared with a control group of healthy volunteers (n = 124). 39 patients (71.8% males, median age 43 years) were reviewed at a mean of 12.7 ± 3.6 months following recovery. One patient without cardiovascular risk factors had post COVID‐19 acute ischaemic limb. Elevated D‐dimer and Factor VIII levels above normal ranges were noted in 17.9% (7/39) and 48.7% (19/39) of patients respectively, with a higher median D‐dimer 0.34 FEU μg/mL (IQR 0.28, 0.46) (p < .001) and Factor VIII 150% (IQR 171, 203) (p = .004), versus controls. Thrombin generation (Thromboscreen) showed a higher median endogenous thrombin potential (ETP) of 1352 nM*min (IQR 1152, 1490) (p = .002) and a higher median peak height of 221.4 nM (IQR 170.2, 280.4) (p = 0.01) and delayed lag time 2.4 min (1.42–2.97) (p = 0.0002) versus controls. Raised vWF:Ag and ICAM‐1 levels were observed in 17.9% (7/39) and 7.7% (3/39) of patients respectively, with a higher median VWF:Ag 117% (IQR 86, 154) (p = 0.02) and ICAM‐1 54.1 ng/mL (IQR 43.8, 64.1) (p = .004) than controls. IL‐6 was noted to be raised in 35.9% (14/39) of patients, with a higher median IL‐6 of 1.5 pg/mL (IQR 0.6, 3.0) (p = 0.004) versus controls. Subgroup analysis stratifying patients by COVID‐19 severity and COVID‐19 vaccination preceding SARS‐CoV‐2 infection did not show statistically significant differences. Hypercoagulability, endothelial dysfunction, and inflammation are still detectable in some patients approximately 1 year after recovery from COVID‐19. We performed a prospective observational study at the National Centre for Infectious Diseases (NCID), Singapore. The study was approved by the National Healthcare Group Domain Specific Research Board (DSRB) and written informed consent was obtained. We followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement for cohort studies in the preparation of this manuscript. Patients ≥21 years of age who were admitted to NCID from January 2020 to July 2021 with laboratory- were performed on fresh samples (primary tubes) on the same day of blood collection, while all other tests were performed on plasma stored under the above-mentioned conditions. Baseline patient characteristics included age, sex, ethnicity, comorbidities, and month of COVID-19 infection from blood sampling at the point of enrolment. Disease severity upon recruitment was classified using the Clinical Spectrum of SARS-CoV-2 Infection by the National Institutes of Health. 12 Clinical data were prospectively collected including oxygen requirement, intensive care unit (ICU) stay, COVID-19 vaccination status, and thrombotic events during acute SARS-COV-2 infection as well as during recovery, were available from the clinical records. A one-off collection of 50 ml of whole blood was obtained from each participant via venepuncture for a point prevalence assessment of the inflammatory, hemostatic, and endothelial profile parameters. In addition, full blood count, fasting glucose, HBA1c, and lipid panel were performed. ICAM-1 and IP-10 (R&D Systems, Abington, England) and high sensitivity IL-6 (Interleukin-6) (ThermoFisher, Waltham, MA) were assayed by enzyme-linked immunosorbent assay, C-reactive protein Thirty-nine COVID-19 patients with a median age of 43 years (IQR 32, 56) were recruited at NCID at a mean of 12.7+/À3.6 months following their COVID-19 diagnosis confirmed by SARS-CoV-2 PCR testing. Twenty-eight (71.8%) were males, with a raised median BMI Table 1 . Recovered COVID-19 patients showed significantly higher biomarkers of hypercoagulability, endotheliopathy, and inflammation compared with the control group (Table 2, Figure 1 ). There were significantly higher levels of D-dimer and Factor VIII, with elevated Ddimer and Factor VIII levels above the normal ranges were noted in The unique pathophysiology of SARS-CoV-2 with its affinity to ACE-2 receptors on endothelial cells leads to direct and indirect endothelial injury and has been shown to cause endothelial dysfunction and endotheliitis in multiple vascular beds. 15 Figure S1 showing High-dimensional characterization of postacute sequelae of COVID-19 Anticipating the long-term cardiovascular effects of COVID-19 Post COVID-19 arterial thromboembolism: a clear and present danger Delayed catastrophic thrombotic events in young and asymptomatic post COVID-19 patients COVID-19 associated coagulopathy in critically ill patients: a hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis ISTH interim guidance on recognition and management of coagulopathy in COVID-19 Severe COVID-19 and coagulopathy: a systematic review and meta-analysis COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year Low incidence of venous thrombosis but high incidence of arterial thrombotic complications among critically ill COVID-19 patients in Singapore Global hemostatic tests demonstrate the absence of parameters of hypercoagulability in non-hypoxic mild COVID-19 patients: a prospective matched study Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation Srivastava a; scientific and standardization committee. Towards standardization of clot waveform analysis and recommendations for its clinical applications Treatment Guidelines for COVID-19. Version 7.0, dated 28 Endothelial cell infection and endotheliitis in COVID-19 The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection Long COVID 19 syndrome: is it related to microcirculation and endothelial dysfunction? Insights from TUN-EndCOV study Persisting endothelial cell activation and hypercoagulability after COVID-19 recovery-the prospective observational ROADMAP-post COVID-19 study Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge Persistent endotheliopathy in the pathogenesis of long COVID syndrome Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19 Markers of immune activation and inflammation in individuals with Postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection Neuropsychological, medical and psychiatric findings after recovery from acute COVID-19: a cross-sectional study ST-segment elevation myocardial infarction in post-COVID-19 patients: a case series Long-term cardiovascular outcomes of COVID-19 Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19 Persistence of SARS CoV-2 S1 protein in CD16+ monocytes in post-acute sequelae of COVID-19 (PASC) up to 15 months post-infection Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection The implications of COVID-19 infection on the endothelium: a metabolic vascular perspective Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial The authors greatly appreciate the efforts of our fellow healthcare workers during this pandemic. Special thanks to Sysmex Corporation (Japan), Diagnostica Stago (France), and All Eights (Singapore) Pte Ltd.for their technical support. The authors declare that they have no conflict of interest. Dr. Bingwen Eugene Fan had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Bingwen Eugene Fan, Yew Woon The data that support the findings of this study are available from the corresponding author upon reasonable request.